Adagio Medical Holdings (ADGM) KOL event summary

Introduction and agenda

• The event focused on presenting and discussing results from the FULCRUM-VT pivotal study for monomorphic ventricular tachycardia, recently highlighted at a major scientific conference.

• Presented at Heart Rhythm Society 2026, with key investigators sharing trial design, results, and future directions.

• The session included presentations by leading electrophysiologists and a Q&A segment for investor and clinician engagement.

KOL background and credentials

• Dr. Verma is a Professor at McGill, Director of Cardiology, principal investigator for FULCRUM-VT, with research grants, advisory roles, and clinical trial leadership.

• Dr. Stevenson, Professor at Vanderbilt, is a leader in cardiac arrhythmia management, past president of the Cardiac Electrophysiology Society, with honoraria and research support from device firms.

• Dr. Hakimi, Medical Director and practicing electrophysiologist, has contributed to both clinical practice and product development.

Market insights and analysis

• VT ablation has been limited by inadequate depth and penetration of existing tools, especially in scarred or thick ventricular tissue.

• Ultra-low temperature ablation (ULTA) offers deeper, more consistent lesion formation without irrigation, reducing fluid overload risk, and is unaffected by scar tissue.

• The technology is seen as a potential first-line therapy for a broad range of VT patients, including those with non-ischemic cardiomyopathy.

• Procedural efficiencies, such as reduced need for general anesthesia and shorter ablation times, may enable broader adoption beyond tertiary centers.